Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade

Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.

Two businessmen pulling a rope, closeup shot tug of war

Addiction-drug focused Indivior PLC yielded somewhat to competitive pressure on two fronts on July 11, withdrawing its earlier 2018 net revenue guidance of $1.13bn-$1.17bn, citing both generic competition for its opioid dependence product Suboxone (buprenorphine/naloxone sublingual film) and slow uptake of the recently launched Sublocade (injectable buprenorphine).

The UK-headquartered company said it can’t reliably provide revised net revenue guidance, but hopes to be able to do so...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.